HKPD
Cellyan Biotechnology Co., Ltd (HKPD) SWOT Analysis Analysis (2026)
No material changes this month.
Strengths
Liquidity is strong with a 3.86 current ratio and 3.75 quick ratio, giving HKPD more near-term flexibility than more levered peers.
Debt intensity is low at 0.13 debt-to-equity, so balance-sheet risk is materially lighter than peers that rely more heavily on leverage.
Net debt to EBITDA is negative at -1.13, indicating net cash positioning that supports resilience versus indebted competitors.
The cash conversion cycle of 67.4 days is manageable for a working-capital business, though it is not a clear peer-leading advantage.
Weaknesses
ROIC is -9.2%, showing capital is not earning its cost and leaving HKPD structurally weaker than profitable peers.
The absence of reported operating and gross margins limits evidence of earnings quality, while peers with disclosed positive margins appear better positioned.
A 67.4-day cash conversion cycle ties up capital for longer than leaner peers, reducing reinvestment flexibility and operating efficiency.
Negative invested-capital returns suggest the business model is not yet translating asset deployment into durable peer-relative value creation.
Opportunities
If working-capital discipline improves, the 67.4-day cash conversion cycle could release cash faster than peers with similarly long operating cycles.
The net cash position provides room to fund operational improvements without immediate balance-sheet strain, unlike more leveraged competitors.
Low debt-to-equity leaves capacity to support growth initiatives more flexibly than peers constrained by higher financing costs.
Peer-relative upside depends on converting liquidity strength into sustained returns, because stronger capital efficiency would narrow the gap with profitable operators.
Threats
Persistent negative ROIC threatens long-term competitiveness because peers generating positive returns can compound capital while HKPD destroys value.
If working capital remains elevated, peers with shorter cash cycles can outpace HKPD on cash generation and reinvestment speed.
The lack of margin disclosure raises execution uncertainty, which can leave HKPD at a disadvantage versus peers with clearer profitability profiles.
Balance-sheet strength may not offset operating underperformance if competitors sustain better margins and returns across the cycle.
Overall Score
HKPD’s peer-relative positioning is weakened by negative ROIC and long cash conversion, while its balance-sheet strength provides only partial offset.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Cellyan Biotechnology Co., Ltd. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
